Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The important notices at the end of this release must be observed.

PRESSRELEASE

Cantourage achieves strong and profitable growth in the first quarter of 2025

·        EBITDA margin of 11 to 13 %* in Q1

·        Revenue of more than EUR 25 million in the first quarter of 2025

·        Already over EUR 36 million at the end of April
‍

Berlin, 20 May 2025 - Cantourage Group SE (hereinafter ‘Cantourage’, ISIN:DE000A3DSV01, www.cantourage.com), Europe's leading listed medical cannabis company, once again confirms the economic clout of its business model in the first quarter of 2025.

Accordingto preliminary figures*, Cantourage achieved an EBITDA margin of between 11 and 13%. This underlines the company's ability to combine strong growth witho perational profitability.

Revenue in the first quarter was over EUR 25 million; at the end of April 2025, revenue totalled over EUR 36 million. The company is thus continuing to grow at a fast pace - while maintaining a stable cost base and scaling the platform efficiently.

‘Profitability is not a future prospect for us, but a reality,’ says Philip Schetter, CEO of Cantourage Group SE. ‘We create growth with substance - through our international market presence, reliable supply chains and a clear quality standard that sets Cantourage apart from the competition.’

_________________________________________________________________________________

About Cantourage

Cantouragei s a leading European company for the production and distribution of medical cannabis. Cantourage enables growers worldwide to sell products in European medical markets. Founded in 2019, the company works with more than 60 cannabis growers from 18 countries. Cantourage ensures the highest pharmaceutical quality standards along the value chain and offers products in all relevant market segments: dried flowers, extracts, dronabinol and cannabidiol. The company has been listed on the Frankfurt Stock Exchange since November 11, 2022 and is listed under the ticker symbol “HIGH”.

Press contacts

Pia Senkel | pia.senkel@tonka-pr.com | +49 (0)173 3702649
Klaas Geller | klaas.geller@tonka-communications.de | +49 (0) 176 74717519

_________________________________________________________________________________

*The key financial figures stated are based on internal calculations and are unaudited and unconsolidated. We reserve the right to make changes during the closing process. Please note that this information is subject to change and must be legally verified.

This announcement does not constitute an offer to the public or a solicitation of anoffer to sell securities to the public, in particular not within the meaning ofRegulation (EU) 2017/1129 (Prospectus Regulation).

‍